THE BRAFT1796A TRANSVERSION IS A PREVALENT MUTATIONAL EVENT IN HUMAN THYROID MICROCARCINOMA
https://doi.org/10.51523/2708-6011.2006-3-1-5
Abstract
The results show that BRAFT1799A mutation is a prevalent event in human thyroid microcarcinomas irrespectively of the genetic background of adult patients. Mutated BRAF might be involved in the control of tumors architecture and growth pattern but its presence does not correlate with manifestations of papillary microcarcinomas (PMC) aggressiveness. Whereas BRAF mutation comprise a common genetic alteration in conventional papillary thyroid carcinoma (PTC) and PMC, a number of differences in mutation-related associations between the two types of tumors rather supports the hypothesis that not all macroscopic PTCs may arise from papillary microcarcinoma.
About the Authors
I. . SedliarouBelarus
V. . Saenko
Belarus
T. . Rogounovitch
Belarus
H. . Namba
Belarus
A. . Abrosimov
Belarus
E. . Lushnikov
Belarus
M. . Matsuse
Belarus
A. . Kumagai
Belarus
M. . Nakashima
Belarus
S. . Meirmanov
Belarus
T. . Hayashi
Belarus
M. . Mine
Belarus
S. . Yamashita
Belarus
References
1. Franceschi S., Boyle P., Maisonneuve P., La Vecchia C., Burt A.D., Kerr D.J. and MacFarlane G.J. The epidemiology of thyroid carcinoma // Crit Rev Oncog. - 1993. - Vol. 4. - P. 25-52.
2. Fink A., Tomlinson G., Freeman J.L., Rosen I.B. and Asa S.L. Occult micropapillary carcinoma associated with benign follicular thyroid disease and unrelated thyroid neoplasms // Mod Pathol. - 1996. - Vol. 9. - Р. 816-820.
3. Yamashita H., Noguchi S., Murakami N., Toda M., Uchino S., Watanabe S. and Kawamoto H. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinomaь // Cancer. - 1999. - Vol. 86. - Р. 842-849.
4. Mercer K.E. and Pritchard C.A. Raf proteins and cancer: B-Raf is identified as a mutational target // Biochim Biophys Acta. - 2003. - Vol. 1653. - Р. 25-40.
5. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E. and Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma // Cancer Res. - 2003. - Vol. 63. - Р. 1454-1457.
6. Xu X., Quiros R.M., Gattuso P., Ain K.B. and Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines // Cancer Res. - 2003. - Vol. 63. - Р. 4561-4567.
Review
For citations:
Sedliarou I., Saenko V., Rogounovitch T., Namba H., Abrosimov A., Lushnikov E., Matsuse M., Kumagai A., Nakashima M., Meirmanov S., Hayashi T., Mine M., Yamashita S. THE BRAFT1796A TRANSVERSION IS A PREVALENT MUTATIONAL EVENT IN HUMAN THYROID MICROCARCINOMA. Health and Ecology Issues. 2006;(1):31-34. (In Russ.) https://doi.org/10.51523/2708-6011.2006-3-1-5